License, Collaboration and Service Agreements - Additional Information (Detail) $ / shares in Units, £ in Millions			1 Months Ended							3 Months Ended							12 Months Ended
	Sep. 21, 2022 USD ($) $ / shares shares	Jan. 15, 2021 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Nov. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2016 USD ($)	Jun. 30, 2016 GBP (£)	May 31, 2016 USD ($)	Mar. 31, 2023 USD ($) $ / shares shares	Sep. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Dec. 31, 2020 USD ($)	Mar. 31, 2019 USD ($)	Dec. 31, 2018 USD ($)	Dec. 31, 2022 USD ($) $ / shares	Nov. 07, 2022 USD ($)	Oct. 31, 2017 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of stock, value													$ 3,626,000
Common stock, par value | $ / shares										$ 0.001							$ 0.001
Proceeds from sale of common stock to related party										$ 0			3,626,000
Revenue recognized										740,000			247,000
Milestone payment										225,000,000.0
Deferred revenue, current										11,845,000							$ 10,369,000
GSK SPA [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of stock, shares | shares	7,450,000
Issuance of stock, value	$ 10,300,000
Remaining transaction price allocated to the performance obligations										64,700,000
Initial Payments to Perform the Obligations										66,000,000.0
Discount on Obligations										1,300,000
GSK SPA [Member] | Research And Development Services Related To Upcoming Milestones [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized										19,000,000.0
GSK SPA [Member] | License and Know-How Transfer [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Remaining transaction price allocated to the performance obligations										64,700,000
Performance Obligation Allocated Transaction Price										45,700,000
Gates M R I [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Reduction to research and development expense										0			0
Vertex License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
License agreement research and development expense related to achievement of regulatory milestones										$ 0			0
Contract termination period										10 years
Nonrefundable upfront payments									$ 500,000
Potential milestone payment upon achievement of specified clinical, regulatory and commercial milestones									$ 80,200,000
Contract termination period if no material development or commercialization occurs										1 year
GSK License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Issuance of stock, shares | shares	7,450,000
Issuance of stock, value	$ 1,300,000
Share price | $ / shares	$ 1.20805
Performance Obligation Allocated Transaction Price										$ 500,000
Deferred revenue, current										18,100,000
GSK License Agreement [Member] | Glaxo Smith Kline [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payment																		$ 66,000,000.0
Reduction In Subsequent Payments by GSK to the Company																		50.00%
Meiji License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Nonrefundable upfront payments						$ 600,000
Sublicense fee payable to counter party										7,500,000
Potential milestone payments upon achievement of specified condition																			$ 1,000,000.0
License agreement fixed assets related payments																$ 1,600,000
Potential milestone payments upon completion and delivery of results of a clinical study										1,000,000.0
Future milestone payments			$ 1,000,000.0
Sublicence Fee Paid to Counter Party																	$ 6,600,000
Savior Service Agreement [Member] | Prepaid Asset [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Non-refundable supervision fee related to commercial manufacturing facility					$ 2,000,000.0
Savior Service Agreement [Member] | Long-term Asset [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Service agreement additional payment related to facility build out costs										5,300,000
Cantab Related Agreements [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Potential milestone payment upon achievement of specified commercial milestone								£ 5.0		6,200,000
License agreement research and development expense related to achievement of regulatory milestones										$ 0			0
Potential milestone payment upon achievement of specified clinical, regulatory and commercial milestones							$ 5,800,000
Everest License Agreement [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Period of option granted on an agreement										12 months
Upfront payment received															$ 3,000.0
Potential milestone payments upon completion and delivery of results of a clinical study														$ 2,000,000.0
Revenue recognized										$ 0			$ 0
Milestone payment										34,000,000.0
Everest License Agreement [Member] | SPR 206 [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received				$ 800,000											2,000,000.0
Potential milestone payments upon completion and delivery of results of a clinical study		$ 1,500,000										$ 700,000
Milestones payment received		$ 2,000,000.0
Everest License Agreement [Member] | SPR 741 [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received															$ 1,000,000.0
Everest License Agreement [Member] | Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Agreement termination period upon written notice		180 days
Everest License Agreement [Member] | Maximum [Member] | SPR 206 [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Receivable amount upon achievement of certain milestone		$ 38,000,000.0								$ 59,500,000
Everest License Agreement [Member] | Minimum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Agreement termination period upon written notice		90 days
Pfizer License and Share Purchase Agreements [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Receivable amount upon achievement of certain milestone			$ 900,000								$ 900,000
Milestones payment received											5,000,000.0
Issuance of stock, shares | shares										2,362,348
Issuance of stock, value										$ 27,500,000
Remaining transaction price allocated to the performance obligations										12,500,000
Revenue recognized										200,000
Premium associated freestanding equity										12,500,000
Performance Obligation Allocated Transaction Price											5,000,000.0
Deferred revenue, current										13,700,000
Pfizer License and Share Purchase Agreements [Member] | SPR 206 [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Receivable amount upon achievement of certain milestone										$ 80,000,000.0
Issuance of stock, shares | shares										2,362,348
Share price | $ / shares										$ 16.93
Proceeds from sale of common stock to related party										$ 40,000,000.0
Pfizer License and Share Purchase Agreements [Member] | Research And Development Services Related To Upcoming Milestones [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Performance Obligation Allocated Transaction Price										11,100,000	$ 4,100,000
Pfizer License and Share Purchase Agreements [Member] | License and Know-How Transfer [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Performance Obligation Allocated Transaction Price										$ 1,400,000